Faron Pharmaceuticals Oy (LSE:FARN) LT-Debt-to-Total-Asset : 0.93 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Faron Pharmaceuticals Oy's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.93.

Faron Pharmaceuticals Oy's long-term debt to total assets ratio declined from Dec. 2022 (1.00) to Dec. 2023 (0.93). It may suggest that Faron Pharmaceuticals Oy is progressively becoming less dependent on debt to grow their business.

Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset Historical Data

The historical data trend for Faron Pharmaceuticals Oy's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.25

0.35

0.22

1.00

0.93

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.22	0.73	1.00	0.86	0.93

Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset Calculation

Faron Pharmaceuticals Oy's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	8.161	/	8.805
	=

Faron Pharmaceuticals Oy's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	8.161	/	8.805
	=

Faron Pharmaceuticals Oy (LSE:FARN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines